OrthoPediatrics Hits the Inflection Point: Free Cash Flow Turns Positive as Super Cycle Ramps
Record Q2 revenue and adjusted EBITDA, a 60% stock rally, and raised guidance highlight a pivotal moment for the pediatric orthopedics pure-play.
KIDS · Earnings Call · 2026-08-04
Inflection Point Reached
OrthoPediatrics (KIDS) has long been a story of growth at the expense of profitability. That narrative changed dramatically in the second quarter of 2026. Revenue grew 15% year-over-year to a record $70.5 million, and adjusted EBITDA hit $6.8 million – also a record. More importantly, free cash flow used fell to just $3.1 million, a 78% improvement from the prior year, setting up the company to achieve its long-promised goal of free cash flow break-even for the full year. The stock has responded, rallying roughly 60% over the last 90 days, and is now within 3% of its recent high. Management's confidence is palpable:
we have reached an inflection point in our financial trajectory, and our results this quarter give us high confidence in our commitment to achieve positive free cash flow in the second half of 2026.
The fundamentals support this optimism. Free cash flow (less SBC) has improved from a use of $19 million in Q2 2025 to just $3 million in Q2 2026, driven by better EBITDA, improved gross margin, and disciplined working capital. The company is also raising its full-year revenue guidance to $265–269 million, representing 12–14% growth, while reiterating adjusted EBITDA guidance of approximately $25 million.
The Innovation Super Cycle
The engine behind this inflection is the super cycle – a multi-year wave of new product launches across trauma, deformity, and scoliosis. While early, the impact is already visible. CEO David Bailey noted on the call, “contribution from the super cycle really was not as strong as it will be certainly in the coming quarters as those sets get deployed” — David Bailey, Chief Executive Officer · 2026-08-04. The first 3P Small Mini cases were performed late in Q2, with full market release expected in early 2027. The 3P Hip system is gaining traction, and VerteGlide continues to train surgeons – now over 124 trained. These products carry higher ASPs and margins, and require less capital to deploy, directly supporting the cash flow story.
The 7D unit sales timing remains a wildcard, but management is clear that the underlying scoliosis business is strong. Excluding the zero 7D units and lower set sales, scoliosis revenue grew in the mid-teens. "We're not here to speculate at this stage, but certainly we expect them to happen," Bailey said about 7D, referencing the lumpy nature of capital sales.
Beyond the Super Cycle: OPSB and International
The OPSB (OrthoPediatrics Specialty Bracing) business continues to shine, growing over 20% with strong same-store sales and new clinic expansion. The launch of DF2, now in 150 children's hospitals, and upcoming products like TRAXIO and TractorFIX, are broadening the company's footprint. International revenue grew 22%, led by record Europe performance, with early contributions from EU MDR approvals for the full T&D portfolio. As Fred Hite said, "very early days" for EU MDR, but the opportunity is large as many competitors have exited the space.
The company's strategic patience is evident. In the prior quarter, management noted, “We have very few sets available on the 3P side at this stage” — David R. Bailey, President and Chief Executive Officer · 2026-04-30, highlighting the deliberate rollout. And earlier, regarding 7D, “We did get some unit placements” — David Bailey, President and Chief Executive Officer · 2026-02-26 – indicating the volatility but also the potential.
With the stock now pricing in the inflection, the question is whether the super cycle can sustain the momentum. Management believes it can, with a pipeline that extends through 2028 and beyond. For a company that has been a story of promise for years, the second quarter of 2026 marks the moment when the promise starts turning into numbers.